| Nov 12 |
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 7 |
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
|
| Nov 5 |
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
|
| Oct 8 |
GSK Arexvy protects from RSV over three full seasons
|
| Oct 4 |
Agenus: Cash Poor + Milestone Rich = Tough Slog Ahead
|
| Sep 13 |
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
|
| Sep 3 |
Agenus to Participate in September Investor Conferences
|
| Aug 8 |
Agenus (AGEN) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Agenus, Inc. (AGEN) Q2 2024 Earnings Call Transcript
|
